Technical Analysis for FRTX - Fresh Tracks Therapeutics
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Downtrend | Bearish | -2.72% | |
Narrow Range Bar | Range Contraction | -2.72% | |
Below Lower BB | Weakness | -2.72% | |
Gapped Down | Weakness | -2.72% | |
Oversold Stochastic | Weakness | -2.72% | |
Stochastic Buy Signal | Bullish | -18.75% | |
Narrow Range Bar | Range Contraction | -18.75% | |
Earnings Movers | Other | -18.75% | |
Oversold Stochastic | Weakness | -18.75% | |
Narrow Range Bar | Range Contraction | -18.75% |
Alert | Time |
---|---|
Gapped Down (Full) | about 3 hours ago |
Fell Below Previous Day's Low | about 3 hours ago |
Down 2 % | about 3 hours ago |
Down 1% | about 3 hours ago |
Gapped Down (Full) | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/11/2024
Fresh Tracks Therapeutics Description
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. The Company’s pipeline aims to disrupt existing treatment paradigms and features several new molecular entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases. Fresh Track Therapeutic’s executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first-in-class products that achieved iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide. The Company’s strategy is to align this experience and clear vision to explore beyond the limitations of current therapies by identifying, pursuing, and developing next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with autoimmune, inflammatory, and other debilitating diseases.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Pharmaceutical Disease Inflammatory
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.1 |
52 Week Low | 0.5603 |
Average Volume | 16,346 |
200-Day Moving Average | 0.91 |
50-Day Moving Average | 0.91 |
20-Day Moving Average | 0.91 |
10-Day Moving Average | 0.88 |
Average True Range | 0.03 |
RSI (14) | 20.00 |
ADX | 25.14 |
+DI | 24.09 |
-DI | 58.20 |
Chandelier Exit (Long, 3 ATRs) | 0.87 |
Chandelier Exit (Short, 3 ATRs) | 0.82 |
Upper Bollinger Bands | 0.99 |
Lower Bollinger Band | 0.82 |
Percent B (%b) | -0.45 |
BandWidth | 19.80 |
MACD Line | -0.02 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0145 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.74 | ||||
Resistance 3 (R3) | 0.74 | 0.74 | 0.74 | ||
Resistance 2 (R2) | 0.74 | 0.74 | 0.74 | 0.74 | |
Resistance 1 (R1) | 0.74 | 0.74 | 0.74 | 0.74 | 0.74 |
Pivot Point | 0.74 | 0.74 | 0.74 | 0.74 | 0.74 |
Support 1 (S1) | 0.74 | 0.74 | 0.74 | 0.74 | 0.74 |
Support 2 (S2) | 0.74 | 0.74 | 0.74 | 0.74 | |
Support 3 (S3) | 0.74 | 0.74 | 0.74 | ||
Support 4 (S4) | 0.74 |